6th OLOMOUC NEUROIMMUNOLOGY SYMPOSIUM
WITH INTERNATIONAL PARTICIPATION
September 16 – 17, 2010
Konvikt – Arts Centre, Palacký University, Olomouc
SYMPOSIUM‘S MAIN TOPICS:
- Modern trends in multiple sclerosis treatment
- Cerebrospinal fluid diagnostics in multiple sclerosis
- Nurse section
Timetable
September 16, 2010 | |||
| Auditorium | Lectorium | Cinema Hall |
17:00 | Opening |
|
|
17:15 | New Treatment Options in MS | ||
18:00 | MRI in Therapy Optimisation | ||
19:00 | Konvikt Courtyard | ||
September 17, 2010 | |||
| Auditorium | Lectorium | Cinema Hall |
9.00 | Welcome and introduction to Day 2 |
|
|
9.15 | Multiple sclerosis: |
|
|
10.00 | Treatment guidelines |
|
|
10.40 | Break | ||
11:00 | Merck Serono |
|
|
12.00 | Lunch | ||
13.00 | Have we changed | Importance of CSF investigations in multiple sclerosis | Multiple sclerosis – disease characteristics |
13.15 | Monoclonal antibodies for multiple sclerosis treatment | New opportunities in multiple sclerosis diagnostics using isoelectric focusing in IgA, IgM class and in FLC | Therapeutic procedures in multiple sclerosis treatments |
13.30 | New MS epidemiological data in Czech Republic | The method and importance of macrophage oxidative burst detection in CSF diagnostics of central nervous system involvement | Modern trends in multiple sclerosis treatment – MxA. Devic‘s disease |
13.45 | Multiple sclerosis and borreliosis: co-incidence or causal relationship? | CSF inflammation and neurodegeneration markers in patients with multiple sclerosis | Natalizumab – mechanism of action and rules for its administration |
14.00 | Laser polarimetry with variable corneal compensation (GDx) measurements of thickness of the retinal layer of the optic nerve – a new method for the monitoring of degenerative changes in multiple sclerosis? | Detection of increased light neurofilament subunit concentrations in cerebrospinal fluid of multiple sclerosis patients | Experimental treatment of malign relapsing-progressive forms of MS |
14.15 | Myelin disorders and demyelination caused by a systemic disease or by side effects of immunomodulatory therapy | Use of flow cytometry for the detection of cell subpopulations in cerebrospinal fluid | Rehabilitation care |
14.30 | Demyelination and remyelination in multiple sclerosis | Current possibilities of laboratory medicine in diagnosing selected neurodegenerative diseases with a special emphasis on multiple sclerosis | Incidence and treatment of decubitus ulcers in patients with multiple sclerosis |
14.45 | Break | ||
15.00 | Neurodegeneration and how to influence it in multiple sclerosis |
| Clinical manifestations |
15.15 | Treatment for juvenile multiple sclerosis |
| Neuropsychiatric manifestations in multiple sclerosis patients |
15.30 | Comprehensive monitoring of a patient with a clinically isolated syndrome |
| Sexual dysfunction |
15.45 | Treatment for aggressive multiple sclerosis |
| Paraclinical exami-nation methods in MS – lumbar puncture |
16.00 | Two-year experience with natalizumab treatment in MS Centre, Department of Neurology, Faculty Hospital Královské Vinohrady, Praha |
| CSF examination |
16.15 | Measuring nerve fibre layer thickness in the retina of patients with multiple sclerosis and optic neuritis |
| Evoked potentials |
16.30 | Fingolimod – promising peroral drug for sclerosis multiplex treatment. Mechanism of action and results of clinical trials |
| Living with multiple sclerosis |